What is included in this Sample?
- * Market Segmentation
- * Key Findings
- * Research Scope
- * Table of Content
- * Report Structure
- * Report Methodology
Download FREE Sample Report
Transcatheter Aortic Valve Implantation (TAVI) Market Size, Share, Growth, and Industry Analysis, By Type (Transfemoral Approach & Transapical Approach), By Downstream industry (Aortic Stenosis & Aortic Regurgitation), and Regional Forecast to 2033
Trending Insights

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) MARKET OVERVIEW
The Transcatheter Aortic Valve Implantation (TAVI) Market, valued at approximately USD 8.51 billion in 2024, is projected to reach USD 9.82 billion in 2025 and further escalate to USD 30.65 billion by 2033, driven by a strong CAGR of about 15.3%.
The transcatheter aortic valve implantation (TAVI) market trend is increasing immensely as ice stenosis is on the rise, especially in the global elderly population. TAVI is a minimally invasive surgery that provides an alternativeive life-saving surgery to conventional open-heart surgery, especially for -risk patients. The market is also growing in connection with advancements in valve technologies, as well as growing regulatory approvals. At present, the market is headed by North America and Europe, with promising future potential in the Asia-Pacificific region as a result of incremental health care investments. As the world is calling for for more and more products that minimize cardiovascular interventions, the TAVI market has prospects of further growth around the world.
TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) MARKET KEY FINDINGS
- Market Size and Growth: It is expected to grow by USD 30.65 billion in 2033 compared to USD 8.51 billion in 2024 at a compound annual growth rate (CAGR) of 15.3 percent.
- Key Market Driver: There has been an explosive growth in transfemoral (TF) TAVI usage, with sheaths becoming 14-16 Fr with fewer vascular complications and less stringent selection criteria.
- Major Market Restraint: In 2021, North America has a share of 61.22% in the global TAVI market, which denotes under-penetration and lack of expertise in other markets.
- Emerging Trends: More streamlined so-called minimalist TF TAVI protocols, which include 14-16 Fr sheaths, percutaneous femoral access, and conscious sedation, are quickly becoming the norm in simple cases.
- Regional Leadership: In 2021, North America had the highest market share of 61.22%, which shows its dominance in TAVI adoption.
- Competitive Landscape: Edwards Lifesciences (TAVI market share 62.95% in 2022) is the most leading one among the 10 players worldwide on the market of TAVI.
- Market Segmentation: In the year 2021, 80.88 percent of the TAVI procedure was done in an aortic stenosis.
- Recent Development: The detailed TAVI report is published on 16 May 2023; the document consists of 102 pages USD and includes the description of 10 key vendors (e.g., Boston Scientific, Edwards Lifesciences and Medtronic).
COVID-19 IMPACT
Transcatheter Aortic valve Implantation (TAVI) Industry Had a Negative Effect Due to Procedure postponements during COVID-19 Pandemic
The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.
The COVID-19 pandemic affected the transcatheter aortic valve implantation (TAVI) market in anadverse way, mainly when the postponement of elective and non-emergency procedures worsened the situation. Due to the changes in the priority of healthcare systems in almost every country to treat COVID-19 cases, a significant number of cardiac interventions, including TAVI, were postponed. This entailed a serious drop-off in volumes of procedures and momentary market stalling. Also, the unwillingness of patients to enter hospitals and the redistribution of medical resources served as a further inhibition of the treatment rates. The general disparity in the supply chains and clinical operations helped to decline the TAVI market in the peak period of the pandemic.
LATEST TRENDS
Market Growth Is Fueled by Valve Innovations and Procedural Advancements
The market of the TAVI is being driven today by the fast pace of innovation of valve innovations and procedural iterations, as well as market growth—most notably on the self-moving and balloon-expanding valves. The self-expanding valve segment is particularly becoming very popular, with about 66.5% of the market in 2024 attributed to its better hemodynamic performances, particularly in patients with smaller annuli or those with complex anatomy. Clinical data in the most recent years indicate self-expanding supra-annular valves are comparable or superior to balloon-expandable valves in durability and reduce paravalvular leaks, which makes them safe to be used in more ways. The tide of regulation is still coming in, with Medtronic getting approval on Evolut 2FX+ in 2024 and Boston Scientific on Acurate Design Prime in 2024, and Abbott now embedding AI guidance into new balloon-expandable products to indicate a potential trend to smart devices. In addition to the technological breakthroughs, the market is trending towards minimalist procedures that can be performed with catheters only and outpatient settings, enhancing the value of safer, faster, and more patient-friendly TAVI approaches.
TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) MARKET SEGMENTATION
By Type
Based on Type, the global market can be categorized into Transfemoral Approach & Transapical Approach
- Transfemoral Approach: TAVI procedures also involve the use of the transfemoral method as the most widely applied mode because of the use of valve delivery via the artery (femoral). It is preferred because it is less invasive with faster recovery and less time in a hospital. Catheter and faster improvements in sheath design have made it safer and applicable in a wider group of patients. Consequently, the method is overwhelming the TAVI market and still gaining popularity worldwide.
- Transapical Approach: This is an approach where the heart is accessed through the tip of the left ventricle, usually when the peripheral arteries are unsuitable for providing transfemoral access. It is more aggressive, and it may be linked with increasing complications during the operation and prolonged recuperation. Because of such shortcomings and increased transfemoral technology, its application has experienced reduced application in past years. Nonetheless, it is an important alternative in certain limited patient groups containing complex anatomic vasculature.
By Application
Based on Downstream industry, the global market can be categorized into Aortic Stenosis & Aortic Regurgitation
- Aortic Stenosis: The main application category that leads to the market of TAVI is aortic stenosis, i.e., the condition in which the aortic valve opening narrows to inhibit blood flow. TAVI has become an essential procedure to replace surgical valve replacement, particularly in the aged and high-risk patients. Rising popularity among aging populations combined with promising clinical results resulted in the spread of the procedures. Further innovations and persistence of data on safety over long periods of time are likely to further enhance its market dominance.
- Aortic Regurgitation: Another relatively smaller but increasing part of the TAVI market is aortic regurgitation, where there is failure of the aortic valve to close normally, causing the blood to leak back into the heart. The reason to treat this condition using TAVI has proven difficult based on anatomical complications and also due to the lack of calcification so as to latch the valve. But there has been a recent development of devices and off-label applications that have shown encouraging results. This segment is set to grow slowly as dedicated devices for this indication are under testing.
MARKET DYNAMICS
Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.
Driving Factors
Market Growth Driven by Aging Population Favoring Less Invasive TAVI
The world population has gained an elderly population, hence contributing to the rise in age-related cardiovascular diseases and, more specifically, aortic stenosis. Older patients tend to have a combination of other diseases that increase the risks of subjecting them to traditional open-heart surgery; thus, TAVI is an ideal option. This is particularly important with older adults, as TAVI is less invasive and thus decreases complications and stays in the hospital as well as recovery time. The demand for the TAVI procedure is still based on this demographic trend around the world.
Innovative Technologies and Procedures Are Driving Market Growth Globally
Safety and efficacy are greatly improved with constant innovations in designing valves, catheter systems, and imaging technologies with TAVI. The new generation valves are more durable, hemodynamically efficient, and have lower risks of paravalvular leaks. MIPs allow shorter recovery periods for patients and use outpatient procedures. These developments are increasing the number of eligible patients and building confidence in the treatment procedure by both the physician and patient, which resulting Transcatheter Aortic Valve Implantation (TAVI) Market growth.
Restraining Factor
High Costs and Limited Access Are Slowing Market Growth
High cost of procedures and devices is also one of the key restraining factors of the transcatheter aortic valve implantation (TAVI) market. Due to the significantly higher costs of the TAVI procedures compared with traditional surgical implants of the valves, they will be too costly to afford in the low- and middle-income areas. Narrow reimbursement coverages and financial limitations of certain healthcare systems also limit the common use. This is a barrier to entry that can be experienced by both patients and providers to slow the entry into this market even though they are clinically advantageous.

Expanding Approvals and Awareness Drive Market Growth Across Groups
Opportunity
Another potential of TAVI market is the increased usage of a system in low- and intermediate-risk groups of patients. Regulatory approvals are expanding as clinical trials further show positive results in these groups of people. This growth greatly increases the applicable patient pool in TAVI procedures. Rising acceptability amongst the cardiologists and patient awareness contribute to the rise in the market as well.

Limited Long-Term Data On Durability Slows Market Growth
Challenge
One of the major issues that the TAVI market is dealing with is the ten-year durability and the performance of transcatheter valves, particularly when it comes to younger individuals. In contrast to surgical valves, which are decades old with a raft of outcome data, TAVI valves do not yet have a lot of long-term evidence. This uncertainty causes the physicians to be cautious when suggesting TAVI to lower-risk, younger people. Maintaining the same performance throughout the time is also important so that the process of embracing the procedure in all classes of people can spread.
-
Request a Free sample to learn more about this report
TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) MARKET REGIONAL INSIGHTS
-
North America
North America's Advanced Healthcare and Innovation Drive Market Growth
The transcatheter aortic valve implantation (TAVI) market is controlled by North America due to its developed health structure, early usage of new innovative heart operations, and prevalence of major medical equipment organizations. The area is also endowed with favorable reimbursement policies and an abundance of aortic valve disorder in the aging population. The United States Transcatheter Aortic Valve Implantation (TAVI) Market is the epicenter of this dominance as it prospers owing to the tremendous study of clinical practice, FDA approvals, and fast-paced adaptation of next-generation TAVI devices. Companies with their operations in the U.S., such as Edwards Lifesciences and Medtronic, are the most innovative and the largest in procedural volumes. All in all, the American leadership in the TAVI market is truly a kick-starter in North America.
-
Europe
Europe's Clinical Adoption and Regulations Boost Strong Market Growth
Europe holds remarkable Transcatheter Aortic Valve Implantation (TAVI) Market share because of its early clinical adoption, advanced healthcare infrastructure, and strong regulatory support. The area is characterized by a high medical development level, organized payment systems, and active participation in big clinical trials. Germany, France, and the UK are the leaders because of the volumes of procedures they have and the developed system of providing cardiac care. The regional manufacturing of medical devices and the European support of regulations accelerate the growth of the market as well.
-
Asia
Aging Population and Investments Fuel Asia’s Rapid Market Growth
The prevalence rate of cardiovascular diseases and the increasing population of the aged are turning Asia into a rapidly growing area in the transcatheter aortic valve implantation (TAVI) market. Greater investments in healthcare and better medical facilities are opening the way to the gradual embrace of advanced cardiac procedures such as TAVI. The emerging technologies are experiencing increasing awareness and trial and approval of clinical devices in countries like China, Japan, and India. The region has good potential for market expansion in the future even though adoption has not yet matured.
KEY INDUSTRY PLAYERS
Key Players’ Innovations and Alliances Accelerate Global Market Growth
Important players in the industry have made some considerable impacts on the TAVI Marshall market by engaging in ongoing innovations, forming strategic alliances, and expanding across the globe. Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott are the pioneers in designing the next generation of valves that promise greater durability, better delivery systems, and low risks involved in the procedure. Such players are in the active business of successful clinical trials and regulatory approvals in order to expand the overall demographics of patients to include low-risk segments as well as younger patients. Moreover, collaboration with hospitals and research centers assists in increasing training and implementation. They are also investing in R&D and international channels of distribution, thus hastening the growth and availability of the TAVI market.
List of Top Transcatheter Aortic Valve Implantation (TAVI) Companies
- Boston Scientific (U.S.)
- Edwards Lifesciences (U.S.)
- Abbott (U.S.)
- MicroPort (China)
- Meril Life Sciences (India)
KEY INDUSTRY DEVELOPMENT
March 2024: A recent and particular industrial development in the TAVI market is the FDA approval of the Evolut™ FX+ TAVR system of Medtronic. The next-generation valve has an altered diamond-like frame, offering a four-times greater window area of coronary access, privileging the operation of the catheter without adverse effects on the valve. Additionally, the device received CE Mark approval in Europe later in October 2024, further enabling its commercial rollout beyond the U.S. This development marks a significant advance in facilitating future coronary interventions.
REPORT COVERAGE
The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential Downstream industrys that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.
This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.
Attributes | Details |
---|---|
Market Size Value In |
US$ 8.51 Billion in 2024 |
Market Size Value By |
US$ 30.65 Billion by 2033 |
Growth Rate |
CAGR of 15.3% from 2025 to 2033 |
Forecast Period |
2025 To 2033 |
Base Year |
2024 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
|
By Type
|
|
By Application
|
FAQs
The global Transcatheter Aortic Valve Implantation (TAVI) Market is expected to reach USD 30.65 billion by 2033.
The Transcatheter Aortic Valve Implantation (TAVI) Market is expected to exhibit a CAGR of 15.3% by 2033.
Expansion of Plant-Based and Dairy-Free Alternatives & Rising Health Consciousness and Demand for Functional Foods are the driving factors to expand the market growth.
The key market segmentation, which includes, based on type, the Transcatheter Aortic valve Implantation (TAVI) Market is Transfemoral Approach & Transapical Approach. Based on Downstream industry, the Transcatheter Aortic valve Implantation (TAVI) Market is classified as Aortic Stenosis & Aortic Regurgitation.